{"disease":{"id":"cancer-metastatic","name":"cancer metastatic"},"drugs":{"marketed":[{"drug_id":"menest","indication_name":"Breast cancer (for palliation only) in appropriately selected women and men with metastatic disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Menest","generic_name":"Estrogens, Esterified","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":10,"revenue":null,"mechanism":"Esterified estrogens, sold under the brand names Estratab and Menest, are used for hormone therapy and cancer treatment."},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-negative tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic hormone receptor-positive breast cancer in patients with disease progression on or after endocrine therapy and prior chemotherapy in the metastatic setting and with a PIK3CA mutation and with a HER2-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor and with a hormone receptor-positive tumor and with a HER2-low tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"fulvestrant-injectable-product","indication_name":"Advanced breast cancer in hormone receptor-positive metastatic breast cancer in patients with disease progression on or after prior chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fulvestrant Injectable Product","generic_name":"fulvestrant-injectable-product","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"estrogen receptor","drug_class":"estrogen receptor degrader","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"fulvestrant-injectable-product","indication_name":"Advanced breast cancer in hormone receptor-positive metastatic breast cancer in patients with disease progression on or after prior endocrine therapy and prior chemotherapy in the metastatic setting","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fulvestrant Injectable Product","generic_name":"fulvestrant-injectable-product","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"estrogen receptor","drug_class":"estrogen receptor degrader","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":15,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06557967","title":"Study on Prevalence and Impact of Brain Metastases on Survival in Lung Cancer by Line of Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":22517,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT05217381","title":"Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status","phase":"","overall_status":"COMPLETED","enrollment_count":18533,"lead_sponsor_name":"MedSIR","has_results":false},{"nct_id":"NCT05384002","title":"An AI Platform Integrating Imaging Data and Models, Supporting Precision Care Through Prostate Cancer's Continuum","phase":"","overall_status":"COMPLETED","enrollment_count":14000,"lead_sponsor_name":"Fondazione del Piemonte per l'Oncologia","has_results":false},{"nct_id":"NCT03577197","title":"Southeast Netherlands Advanced Metastatic Breast Cancer Registry","phase":"","overall_status":"RECRUITING","enrollment_count":7000,"lead_sponsor_name":"Academisch Ziekenhuis Maastricht","has_results":false},{"nct_id":"NCT00068003","title":"Harvesting Cells for Experimental Cancer Treatments","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":7000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06835218","title":"PROCARE - PROstate Cancer Real World Evidence Registry","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"UroTrials Company (GmbH)","has_results":false},{"nct_id":"NCT06805812","title":"Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT07386847","title":"A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT03461341","title":"European iNvestigation of SUrveillance After Resection for Esophageal Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":3000,"lead_sponsor_name":"St. James's Hospital, Ireland","has_results":false},{"nct_id":"NCT04817956","title":"Improving Public Cancer Care by Implementing Precision Medicine in Norway","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Oslo University Hospital","has_results":false},{"nct_id":"NCT05564377","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":2900,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06864338","title":"Pilot Study for Colorectal Cancer and Advanced Adenoma Detection With the Mainz Biomed Colorectal Cancer Test","phase":"","overall_status":"RECRUITING","enrollment_count":2700,"lead_sponsor_name":"Mainz Biomed","has_results":false},{"nct_id":"NCT07009743","title":"O-RADS MRI System on Early Detection of Ovarian Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2549,"lead_sponsor_name":"Shanghai Gynecologic Oncology Group","has_results":false},{"nct_id":"NCT05537922","title":"I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy","phase":"","overall_status":"RECRUITING","enrollment_count":2200,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT07484971","title":"Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Société Algérienne de Formation et Recherche en Oncologie","has_results":false},{"nct_id":"NCT07112599","title":"Study of Predicting Lymph Node Metastasis of High-risk Prostate Cancer by Artificial Intelligence Multi-omics Analysis","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Anhui Medical University","has_results":false},{"nct_id":"NCT05933876","title":"The Impact of Radiotherapy on Oligometastatic Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Institut Investigacio Sanitaria Pere Virgili","has_results":false},{"nct_id":"NCT06342440","title":"Early Detection of Advanced Adenomas and Colorectal Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT06725628","title":"Multiomics Study of Biological Behavior of Lymph Node Metastasis in Papillary Thyroid Carcinoma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Tianhan Zhou","has_results":false},{"nct_id":"NCT05908799","title":"Emulation of the KEYNOTE-189 Trial Using Electronic Health Records","phase":"","overall_status":"COMPLETED","enrollment_count":1854,"lead_sponsor_name":"Aetion, Inc.","has_results":false},{"nct_id":"NCT06204302","title":"An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States","phase":"","overall_status":"COMPLETED","enrollment_count":1800,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04314401","title":"National Cancer Institute \"Cancer Moonshot Biobank\"","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1600,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03786107","title":"HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib","phase":"","overall_status":"TERMINATED","enrollment_count":1583,"lead_sponsor_name":"Puma Biotechnology, Inc.","has_results":false},{"nct_id":"NCT02066961","title":"A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":1533,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT02200614","title":"Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1509,"lead_sponsor_name":"Bayer","has_results":true},{"nct_id":"NCT03396874","title":"Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1435,"lead_sponsor_name":"University of Michigan","has_results":true},{"nct_id":"NCT07222566","title":"Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1410,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT02051218","title":"Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1380,"lead_sponsor_name":"Swiss Cancer Institute","has_results":false},{"nct_id":"NCT06136624","title":"Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1310,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT07266350","title":"A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for the Treatment of Cervical Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1300,"lead_sponsor_name":"Qi Zhou","has_results":false},{"nct_id":"NCT07089550","title":"PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN)","phase":"","overall_status":"RECRUITING","enrollment_count":1300,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT01322490","title":"A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1297,"lead_sponsor_name":"Bavarian Nordic","has_results":true},{"nct_id":"NCT03280303","title":"Palbociclib in Real World Practice","phase":"","overall_status":"COMPLETED","enrollment_count":1285,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05339568","title":"Patient's Whole Process Follow-up Management(HOPE-1)","phase":"","overall_status":"RECRUITING","enrollment_count":1268,"lead_sponsor_name":"Qianfoshan Hospital","has_results":false},{"nct_id":"NCT07167095","title":"90-Day Mortality After Emergency Department Discharge in Advanced Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":1250,"lead_sponsor_name":"Ankara Etlik City Hospital","has_results":false},{"nct_id":"NCT06364631","title":"CARE1 Pragmatic Clinical Trial","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1250,"lead_sponsor_name":"Gustave Roussy, Cancer Campus, Grand Paris","has_results":false},{"nct_id":"NCT03682068","title":"Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1246,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06957678","title":"AI-Based Prediction of Lymph Node Metastasis in Gastric Cancer Using Preoperative Multimodal Data","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1200,"lead_sponsor_name":"Qun Zhao","has_results":false},{"nct_id":"NCT04784715","title":"Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1157,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05945732","title":"DESTINY Breast Respond HER2-low Europe","phase":"","overall_status":"RECRUITING","enrollment_count":1155,"lead_sponsor_name":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","has_results":false},{"nct_id":"NCT06445062","title":"Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":1130,"lead_sponsor_name":"Revolution Medicines, Inc.","has_results":false},{"nct_id":"NCT06440902","title":"Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNA","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":1100,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT05701007","title":"Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland","phase":"","overall_status":"COMPLETED","enrollment_count":1083,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07233928","title":"Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Cancers","phase":"NA","overall_status":"RECRUITING","enrollment_count":1050,"lead_sponsor_name":"Institut Claudius Regaud","has_results":false},{"nct_id":"NCT02380274","title":"Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)","phase":"","overall_status":"COMPLETED","enrollment_count":1030,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT05381311","title":"Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study","phase":"","overall_status":"COMPLETED","enrollment_count":1020,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT07243132","title":"Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study)","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"GFPC Investigation","has_results":false},{"nct_id":"NCT03896958","title":"The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"SpeciCare","has_results":false},{"nct_id":"NCT06963723","title":"Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Alliance Foundation Trials, LLC.","has_results":false},{"nct_id":"NCT00923221","title":"Collection of Blood From Patients With Prostate Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}